In multiple myeloma, a high-dose conditioning treatment prior to stem cell transplant
Prescribing Information Important Safety Information

    Common Adverse Reactions

    Evomela®—Safety profile

    Adverse reactions chart

    Selected Important Safety Information

    Adverse Events

    • The most common adverse reactions observed in at least 50% of patients with multiple myeloma treated with Evomela® were neutrophil count decreased, white blood cell count decreased, lymphocyte count decreased, platelet count decreased, diarrhea, nausea, fatigue, hypokalemia, anemia, and vomiting.1
    • For myeloablative conditioning in multiple myeloma patients undergoing ASCT, twelve (20%) patients experienced a treatment emergent serious adverse reaction while on study. The most common serious adverse reactions (>1 patient, 1.6%) were pyrexia, hematochezia, febrile neutropenia, and renal failure. Treatment-related serious adverse reactions reported in >1 patient were pyrexia (n=2, 3%), febrile neutropenia (n=2, 3%), and hematochezia (n=2, 3%).1
    Reference
    1. Evomela® Prescribing Information. Acrotech Biopharma Inc.
    Important Safety Information
    Click to Hide Advanced Floating Content
    Important Safety Information
    Warnings and Precautions

    Bone Marrow Suppression: For patients receiving EVOMELA as part of a conditioning regimen, myeloablation occurs in all patients. Do not begin the conditioning regimen if a stem cell product is not available for rescue. Monitor complete blood counts, provide supportive care for infections, anemia and thrombocytopenia until there is adequate hematopoietic recovery.

    See More